Physician profile
John M Lim
NPI 1508851346
$6,895.26
in general payments reported to CMS, 2019-2025
25 companies · $805 in 2025
The $805 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,364 · 2020: $611 · 2021: $1,017 · 2022: $836 · 2023: $548 · 2024: $713 · 2025: $805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,066.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,066.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,312.36 | 2019-2025 | Lensx, Tryptyr, Clareon |
| Abbvie INC. | $1,162.60 | 2019-2025 | |
| Allergan, INC. | $596.06 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $553.90 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $457.63 | 2019-2023 | |
| Johnson & Johnson Surgical Vision, INC. | $455.45 | 2019-2023 | |
| Aerie Pharmaceuticals, INC. | $427.35 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $342.69 | 2023-2025 | Envista Envy Iol, Envista Mx60 Iol, Vyzulta |
| Kala Pharmaceuticals, INC. | $305.53 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $236.95 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $156.32 | 2019-2021 | |
| Oyster Point Pharma, INC. | $143.08 | 2022-2024 | Tyrvaya, Ryzumvi |
| Ocular Therapeutix, INC. | $131.61 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $121.00 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $118.38 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $95.39 | 2024-2025 | Vevye |
| Carl Zeiss Meditec USA, INC. | $76.94 | 2024 | Cirrus Hd-Oct |
| Horizon Therapeutics Plc | $46.30 | 2020-2022 | |
| Thea Pharma INC. | $37.28 | 2024 | Iyuzeh |
| Amgen INC. | $36.11 | 2025 | Tepezza |
| Shire North American Group INC | $19.40 | 2019 | |
| Akorn, INC. | $18.27 | 2020 | |
| Rxsight INC | $16.52 | 2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Eyepoint US, INC. | $15.77 | 2019 | |
| Mallinckrodt Enterprises LLC | $12.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.